Ohtuvayre is administered twice daily by a jet nebulizer, with sessions lasting between five minutes and seven minutes. Verona charges $2,950 for a monthly dose of Ohtuvayre. The $35,400 annual ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing the rate of exacerbations over a 24-week period. The ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

The majority pay zero, Lee said. It's important to note Ohtuvayre is a nebulizer, a device that turns a liquid drug into an inhaled mist. But that hasn't been an impediment to uptake. Management ...

Program Updates and Key Milestones Ohtuvayre’s product specific J-code ... program for the maintenance treatment of COPD via a nebulizer. Results will support initiation of a Phase 2b trial ...

FDA approval for advanced products like Verona Pharma's Ohtuvayre in June 2024 underscores the segment's growth potential. Vented nebulizers are expected to witness the fastest growth during the ...